AstraZeneca (AZN) has disclosed a new risk, in the Environmental / Social category.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AstraZeneca faces significant business risks if it fails to meet its sustainability targets and regulatory requirements concerning environmental issues. As healthcare systems adopt net-zero climate targets, the scrutiny from investors, governments, and NGOs on AstraZeneca’s environmental performance is intensifying. The company’s use of specific materials in manufacturing is under increased regulation, which could lead to supply chain disruptions and financial impacts if not managed proactively. Additionally, failure to enhance its environmental sustainability could result in reputational damage and a competitive disadvantage, adversely affecting AstraZeneca’s financial outcomes.
Overall, Wall Street has a Strong Buy consensus rating on AZN stock based on 7 Buys.
To learn more about AstraZeneca’s risk factors, click here.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue